medigraphic.com
Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado

2013, Number 4

<< Back Next >>

Rev Esp Med Quir 2013; 18 (4)

Mitochondrial DNA Mutation and its Relation to Breast Cancer

Tenorio TJA

Language: Spanish
References: 30
Page: 345-349
PDF size: 314.47 Kb.


ABSTRACT

Breast cancer ranks second of all malignancies in the world (1.38 million, 10.9%), only behind lung cancer. According to publications, more than a million of cases are diagnosed around the world, which cause 548,000 deaths in women. In Mexico, breast cancer mortality rate is 14.9 deaths per 100,000 women aged 25 years. The 60% of women who die are between 30 and 59 years old. Etiology of this disease is unknown, however, it is considered to be a multifactorial disease. Although genetic factors have been identified as BRCA-1 and 2, and it is reported that 15-20% of patients with this cancer have a family history, nowadays, the genes responsible have not been identified, and the largest percentage of women with this cancer are sporadic cases. Therefore, the study of genetic variants hampering cell bioenergetics and molecular biology of the tumor, are of major importance for understanding sporadic breast cancer and the consequent development of therapeutic strategies. There are descriptions of a wide variety of mitochondrial disorders associated with breast cancer. The objective of this paper is to review these factors.


REFERENCES

  1. Ferlay J, Pisan P, Parkin DM. Cancer incidence, mortality and prevalence worldwide. IARC Cancer Base 2005, no. 5, version 2.0. Lyon: IARC Press.

  2. Boyle P, Ferlay J. Cancer incidence and mortality in Europe, 2004. Ann Oncol 2005;16:481-488.

  3. SSA México. Boletín de información estadística [en línea]. Consultado en http://sinais.salud.gob.mx/publicaciones. México: Secretaría de Salud, 2008.

  4. SSA México. Información para la rendición de cuentas. Consultado en http://estadistica.inmujeres.gob.mx/formas/ tarjetas/Cancer_mama_y_cervix1.pdf. México: Secretaría de Salud, 2008.

  5. Knaul FM, Nigenda G, Lozano R, Arreola-Ornelas H. Breast cancer in Mexico: an urgent priority. Salud Publica Mex 2009;51:s335-344.

  6. Rodríguez-Cuevas S, Macías-Martínez CG, Labastida- Almendaro S. Breast cancer in Mexico. Is it a young women disease? Ginecol Obstet Mex 2000;68:185-190.

  7. Rodríguez-Cuevas SA, Capurso-Garcia M. Epidemiology of breast cancer. Ginecol Obstet Mex 2006;74:585-593.

  8. Pharoah PD, Antoniou AC, Easton DF, Ponder BA. Polygenes, risk prediction, and targeted prevention of breast cancer. N Engl J Med 2008;358:2796-2803.

  9. Mincey BA. Genetics and the management of women at high risk for breast cancer. Oncologist 2003;8:466-473.

  10. Katz ES, Dubois-Marshall AH, Sims P, Gautier H, et al. An in vitro model that recapitulates the epithelial to mesenchymal transition (EMT) in human breast cancer. PLoS One 2001;6:e17083.

  11. Formentini LI, Martínez-Reyes I, Cuezva JM. The mitochondrial bioenergetic capacity of carcinomas. IUBMB Life 2010;62:554-560.

  12. Warburg O. On the origin of cancer cells. Science 1956;123:309-314.

  13. Barger JF, Plas DR. Balancing biosynthesis and bioenergetics: metabolic programs in oncogenesis. Endocr Relat Cancer 2010;17:R287-304.

  14. Kelly DP, Scarpulla RC. Transcriptional regulatory circuits controlling mitochondrial biogenesis and function. Genes Dev 2004;18:357-368.

  15. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.

  16. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-674.

  17. Ralph SJ, Rodríguez-Enríquez S, Neuzil J, Moreno-Sánchez R. Bioenergetic pathways in tumor mitochondria as targets for cancer therapy and the importance of the ROS-induced apoptotic trigger. Mol Aspects Med 2010;31:29-59.

  18. Wang XF, Witting PK, Salvatore BA, Neuzil J. Vitamin E analogs trigger apoptosis in HER2/erbB2-overexpressing breast cancer cells by signaling via the mitochondrial pathway. Biochem Biophys Res Commun 2005;326:282-289.

  19. Willers IM, Cuezva JM. Post-transcriptional regulation of the mitochondrial H(+)-ATP synthase: A key regulator of the metabolic phenotype in cancer. Biochim Biophys Acta 2010, oct 27. [Epub ahead of print.]

  20. Chen G, Wang F, Trachootham D, Huang P. Preferential killing of cancer cells with mitochondrial dysfunction by natural compounds. Mitochondrion 2010;10:614-625.

  21. Osthus RC, Shim H, Kim S, Li Q, et al. Deregulation of glucose transporter 1 and glycolytic gene expression by c-Myc. J Biol Chem 2000;275:21797-21800.

  22. Sanchez-Cenizo L, Formentini L, Aldea M, Ortega AD, et al. Up-regulation of the ATPase inhibitory factor 1 (IF1) of the mitochondrial H+-ATP synthase in human tumors mediates the metabolic shift of cancer cells to a Warburg phenotype. J Biol Chem 2010;285:25308-25313.

  23. Kazuno AA, Munakata K, Nagai T, Shimozono S, et al. Identification of mitochondrial DNA polymorphisms that alter mitochondrial matrix pH and intracellular calcium dynamics. PLoS Genet 2006;2:e128.

  24. Fridlyand LE, Philipson LH. Cold climate genes and the prevalence of type 2 diabetes mellitus. Med Hypotheses 2006;67:1034-1041.

  25. Ingman M, Gyllensten U. Rate variation between mitochondrial domains and adaptive evolution in humans. Hum Mol Genet 2007;16:2281-2287.

  26. Jiménez-Sánchez G, Silva-Zolezzi I, Hidalgo A, March S. Genomic medicine in Mexico: initial steps and the road ahead. Genome Res 2008;18:1191-1198.

  27. Balloux F, Handley LJ, Jombart T, Liu H. Manica A. Climate shaped the worldwide distribution of human mitochondrial DNA sequence variation. Proc Biol Sci 2009;276:3447- 3455.

  28. Plak K, Czarnecka AM, Krawczyk T, Golik P, Bartnik E. Breast cancer as a mitochondrial disorder (Review). Oncol Rep 2009;21:845-851.

  29. Tan DJ, Bai RK Wong LJ. Comprehensive scanning of somatic mitochondrial DNA mutations in breast cancer. Cancer Res 2002;62:972-976.

  30. Crisma M, Formaggio F, Moretto A, Toniolo C. Peptide helices based on alpha-amino acids. Biopolymers 2006;84:3-12.




2020     |     www.medigraphic.com